ATHE — Alterity Therapeutics Limited
$2.09-2.79%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ATHE in the TickerWise workspace.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: AU
- Exchange: NASDAQ Capital Market
- Employees: 10
- Website: https://alteritytherapeutics.com
Latest SEC filings for ATHE
Latest ATHE news
- Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference Read article
- Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.